Castration-resistant prostate cancer: AUA Guideline Amendment 2015

Journal of Urology

Volumn 195, Issue 5, 2016, Pages 1444-1452

  Lowrance, William T ^a   Roth, Bruce J ^a   Kirkby, Erin ^a   Murad, Mohammad Hassan ^a   Cookson, Michael S ^a  

^a American Urological Association   (United States)

Author keywords

androgen antagonist; drug therapy; prostatic cancer, castration resistant

Indexed keywords

ABIRATERONE; ANDROSTENEDIONE; DOCETAXEL; ENZALUTAMIDE; PRASTERONE; PREDNISONE; SIPULEUCEL T;

ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER INCIDENCE; CANCER PATIENT; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL PRACTICE; FATIGUE; HUMAN; HYPERTENSION; MEDICAL SOCIETY; META ANALYSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; SYSTEMATIC REVIEW; DISEASE MANAGEMENT; MALE; PATIENT PREFERENCE; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT;

DISEASE MANAGEMENT; HUMANS; MALE; PATIENT PREFERENCE; PRACTICE GUIDELINES AS TOPIC; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT;

EID: 84962950760     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2015.10.086     Document Type: Article

References (22)

1. R.L. Siegel, K.D. Miller, and A. Jemal Cancer statistics, 2015 CA Cancer J Clin 65 2015 5
2. R.B. Montgomery, E.A. Mostaghel, R. Vessella, and et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth Cancer Res 68 2008 4447
3. J.L. Mohler, M.A. Titus, S. Bai, and et al. Activation of the androgen receptor by intratumoral bioconversion of androstanediol to dihydrotestosterone in prostate cancer Cancer Res 71 2011 1486
4. I.F. Tannock, R. de Wit, W.R. Berry, and et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer N Engl J Med 351 2004 1502
5. D.P. Petrylak, C.M. Tangen, M.H.A. Hussain, and et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer N Engl J Med 351 2004 1513
6. H.I. Scher, K. Fizazi, F. Saad, and et al. Increased survival with enzalutamide in prostate cancer after chemotherapy N Engl J Med 367 2012 1187
7. J.S. de Bono, C.J. Logothetis, A. Molina, and et al. Abiraterone and increased survival in metastatic prostate cancer N Engl J Med 364 2011 1995
8. P.W. Kantoff, C.S. Higano, N.D. Shore, and et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer N Engl J Med 363 2010 411
9. J.S. de Bono, S. Oudard, M. Ozguroglu, and et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomized open-label trial Lancet 376 2010 1147
10. C. Parker, S. Nilsson, D. Heinrich, and et al. Alpha emitter radium-223 and survival in metastatic prostate cancer N Engl J Med 369 2013 213
11. M.R. Smith, F. Saad, R. Coleman, and et al. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomized, placebo-controlled trial Lancet 379 2012 39
12. M. Faraday, H. Hubbard, B. Kosiak, and et al. Staying at the cutting edge: a review and analysis of evidence reporting and grading; the recommendations of the American Urological Association BJU Int 104 2009 294
13. M.S. Cookson, B.J. Roth, P. Dahm, and et al. Castration-resistant prostate cancer: AUA guideline J Urol 190 2013 429
14. M.S. Cookson, W.T. Lowrance, M.H. Murad, and et al. Castration-resistant prostate cancer: AUA guideline amendment J Urol 193 2014 491
15. D. Atkins, D. Best, P.A. Briss, and et al. GRADE Working Group. Grading quality of evidence and strength of recommendations BMJ 328 2004 1490
16. H.I. Scher, S. Halabi, I. Tannock, and et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group J Clin Oncol 26 2008 1148
17. C.J. Ryan, M.R. Smith, J.S. de Bono, and et al. Abiraterone in metastatic prostate cancer without previous chemotherapy N Engl J Med 368 2013 138
18. C.J. Ryan, M.R. Smith, K. Fizazi, and et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naïve men with metastatic castration-resistant prostate cancer (COI-AA-302): final overall survival analysis of a randomized, double-blind, placebo-controlled phase 3 study Lancet Oncol 16 2015 152
19. C. Tran, S. Ouk, N.J. Clegg, and et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer Science 324 2009 787
20. T.M. Beer, A.J. Armstrong, D.E. Rathkopf, and et al. Enzalutamide in metastatic prostate cancer before chemotherapy N Engl J Med 371 2014 424
21. M.R. Smith, W.C. Lee, J. Brandman, and et al. Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer J Clin Oncol 23 2005 7897
22. V.B. Shahinian, Y.F. Kuo, J.L. Freeman, and et al. Risk of fracture after androgen deprivation for prostate cancer N Engl J Med 352 2005 154